Current measurement results (mean and range) | |||
Schober or modified Schober (0.5 - 21) | 8.2 (0.5 - 21) | 7.0 (1 - 18) | 0.33 |
Wall to occiput (0 - 37) | 2.8 (0 - 37) | 2.7 (0 - 31) | 0.90 |
Lateral flexion (0 - 61) | 13.7 (0 - 61) | 11.7 (5 - 22) | 0.54 |
Chest wall expansion (0 - 7) | 3.8 (0.5 - 7) | 3.7 (0 - 7) | 0.86 |
CRP (0.1 - 107) | 4.3 (0.2 - 23.5) | 4.0 (0.2 - 20) | 0.81 |
ESR (1 - 63) | 15.9 (1 - 63) | 12.6 (1 - 45) | 0.36 |
TJC (0 - 28) | 0.79 (0 - 10) | 1.02 (0 - 28) | 0.81 |
SJC (0 - 17) | 0.91 (0 - 17) | 0.42 (0 - 7) | 0.31 |
HAQ (0 - 3) | 0.8 (0 - 2.4) | 0.5 (0 - 2) | 0.06 |
Patient Global VAS (0 - 10) | 3.8 (0 - 9) | 4.0 (0 - 10) | 0.64 |
MD Global VAS (0 - 10) | 3.05 (0 - 8) | 3.2 (0 - 9) | 0.80 |
BASDAI (0 - 9.6) | 4.1 (0 - 9.6) | 3.9 (0 - 9.3) | 0.53 |
Current treatment | |||
Nonsteroidal anti-inflammatory drug (NSAID) (%) | 43 | 53 | 0.26 |
Methotrexate (%) | 4 | 9 | 0.33 |
Sulfasalazine (%) | 3 | 6 | 0.43 |
Steroids (%) | 0 | 3 | 0.18 |
Biologics (%) | 47 | 41 | 0.52 |
Previous drugs not currently taking | |||
NSAID (%) | 47 | 39 | 0.33 |
Methotrexate (%) | 16 | 9 | 0.22 |
Sulfasalazine (%) | 19 | 10 | 0.17 |
Steroids (%) | 11 | 9 | 0.60 |
Biologics (%) | 10 | 17 | 0.24 |
% with treatment change at current visit | 29 | 29 | 0.72 |
Reasons for no change despite active disease | |||
Patient refused (N) | 6 | 6 | |
Not in steady state yet (N) | 6 | 3 | |
Contraindicated or comorbidity (N) | 8 | 4 | |
Other (N) | 6 | 3 |